STOKE THERAPEUT.DL-,001

Stoke Therapeutics shares rose in premarket trading after JPMorgan added the stock to its coverage with an "Overweight" rating and a $40 price target. Analyst coverage now totals 14 observers, with no hold or sell recommendations, and the rating aligns with positive coverage from Goldman Sachs, Guggenheim and Wedbush. Stoke also granted incentive stock options to seven new employees and completed recruitment of 162 patients for the Phase 3 EMPEROR study of zorevunersen. The company has funds expected to support operations into early 2028, leaving further upside potential if development progresses. » More on de.investing.com

At a growth conference, Stoke Therapeutics said the Phase III EMPEROR trial has exceeded its target with 162 patients recruited and has seen no study discontinuations to date. The company sees signs of disease‑modifying effects of Zorevunersen in Dravet syndrome in addition to a strong reduction in seizures and plans a rolling regulatory submission starting in Q1 2027, with Phase III data expected in Q3 2027. Stoke also expects 2027 efficacy data for the OSPREY program targeting autosomal‑dominant optic atrophy and emphasized that long‑term data will be central for reimbursement decisions and product labeling. » More on de.investing.com

Stoke Therapeutics reported Q2 2026 revenue of $9.33 million (forecast $5.19 million) with an adjusted loss of $0.93 per share (forecast -$0.77). Recruitment for the Phase III EMPEROR study of Zorevunersen reached 162 patients with no study dropouts, and management plans a rolling NDA submission starting in Q1 2027 targeting a U.S. launch in early 2028. After an at‑the‑market equity offering, pro‑forma cash stands at about $420 million, which the company says should fund operations through potential approval. » More on de.investing.com